Edition:
United Kingdom

Cambrex Corp (CBM.N)

CBM.N on New York Stock Exchange

56.30USD
19 Jan 2018
Change (% chg)

$0.30 (+0.54%)
Prev Close
$56.00
Open
$55.80
Day's High
$56.35
Day's Low
$55.75
Volume
47,860
Avg. Vol
80,894
52-wk High
$62.50
52-wk Low
$42.55

Chart for

About

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the... (more)

Overall

Beta: 2.33
Market Cap(Mil.): $1,842.68
Shares Outstanding(Mil.): 32.73
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Cambrex & Astrazeneca Hold Ceremony To Mark Long-Term Supply Agreement At Karlskoga, Sweden Facility

* CAMBREX & ASTRAZENECA HOLD CEREMONY TO MARK LONG-TERM SUPPLY AGREEMENT AT KARLSKOGA, SWEDEN FACILITY Source text for Eikon: Further company coverage:

16 Jan 2018

BRIEF-Cambrex reports Q3 adjusted earnings per share $0.55 from continuing operations

* Q3 adjusted earnings per share $0.55 from continuing operations

07 Nov 2017

BRIEF-Cambrex appoints Gregory Brown to its board of directors

* Gregory B. Brown M.D. Appointed to the board of directors of Cambrex corporation

03 Nov 2017

BRIEF-Cambrex Corp invests $24 mln in a new facility

* ‍To invest $24 million in a new facility to manufacture highly potent APIs at its Charles City, Iowa plant​ Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Cambrex Corp Q2 revenue $134.6 million

* Q2 adjusted earnings per share $0.76 from continuing operations

04 Aug 2017

Earnings vs. Estimates